weeks. Levels of roxithromycin in serum were obtained from uninfected mice that were fed 10 mg of the drug per day. Samples were collected by axillary bleeding at 0, 3, 6, 9, 24, 48, and 96 h after the start of therapy. Levels Tachyzoites of the virulent RH strain of T. gondii were harvested and prepared as described previously (9) and suspended at 103, 104, and 105 organisms per ml in phosphate-buffered saline. The organisms were injected intraperitoneally in a volume of 0.2 ml, and the mice were monitored for time to death and percent mortality. There were 10 mice per group. All survivors remained clinically healthy 4 weeks after the discontinuation of roxithromycin. They were then sacrificed, and homogenates of their liver, spleen, and brain were injected intraperitoneally into normal mice to assess residual infection. Residual infection was demonstrated by the ability of the subinoculum to kill mice injected with the organs of survivors. In preliminary experiments, fewer than 10 organisms of the RH strain injected in homogenates of normal murine liver, spleen, or brain killed 100% of the mice (11) .
A dose-response experiment with the early-treatment regimen demonstrated significant protection against 2 x 103 organisms at doses of 7.5 mg/day (60% mortality, P < 0.05) and 10 mg/day (10% mortality, P < 0.001), when compared with the control regimen (100% mortality) ( To evaluate the efficacy of roxithromycin against toxoplasmosis under more stringent conditions, we used the delayed-treatment regimen comparing roxithromycin (10 mg/day) with P-S (0.044 and 5 mg/day). The dosage of P-S used was previously found to be effective in the treatment of murine toxoplasmosis (3). P-S (10% mortality) was more effective in preventing death than was roxithromycin (50% mortality), although the difference was not statistically significant (P > 0.05; Table 1 ).
Our results indicate that the new macrolide, roxithromycin, at a dose of 10 mg orally per day, is effective in the treatment of acute infection with T. gondii RH in mice. However, this dose of roxithromycin was less effective in preventing death than was the standard treatment, P-S. Therefore, roxithromycin may offer a safe alternative therapy against toxoplasma infection. Further studies in this regard are warranted.
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